Dovbysh I. M., Bachurin G. V.

DYNAMICS OF THE CONCENTRATION OF PROFIBROGENIC BIOMARKERS IN BLOOD AND URINE IN PATIENTS WITH ACUTE UPPER URINARY TRACT OBSTRUCTION

---

Show/Download

About the author:

Dovbysh I. M., Bachurin G. V.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

Renal calculi most often lead to impaired urine flow. They occur in 40-43% of urological patients. Patients with urolithiasis always have an increased risk of developing acute or chronic kidney disease with impaired renal function and changes in its morphological structure, regardless of the size of the stone and the duration of its stay in the upper urinary tract. The analysis of the literature of the last five years has shown the crucial role of transforming growth factor-β (TGF-β), monocyte chemoattractant protein-1 (MCP-1) and insulin-like growth factor-1 (IGF-1) in the development of renal fibrosis during acute upper urinary tract obstruction (AUUTO). Their complex interactions and dynamics in serum and urine reflect the progression of renal damage and fibrosis and can be used as biomarkers of renal fibrosis. The study aimed to determine the dynamics of profibrogenic biomarkers in blood and urine in acute ureteral obstruction. We studied 50 patients with unilateral acute upper urinary tract obstruction. The concentration of TGF-β, MCP-1, IGF-1 in blood and urine was determined by enzyme-linked immunosorbent assay. In acute upper urinary tract obstruction in patients during the first 7 days, the levels of profibrogenic biomarkers (TGF-β, MCP-1, IGF-1) in the urine significantly increased, indicating the possible onset of sclerotic changes in the kidneys. TGF-β, MCP-1 and, to a lesser extent, IGF-1 in blood and urine are markers of renal fibrosis development in acute upper urinary tract obstruction. Their dynamic changes in serum and urine reflect the progression of renal damage and can provide valuable information about disease mechanisms and potential therapeutic approaches.

Tags:

Bibliography:

1. Dirie NI, Adam MH, Garba B, Dahie HA, Sh Nur MA, Mohamed FY, et al. The prevalence of urolithiasis in subjects undergoing computer tomography in selected referral diagnostic centers in Mogadishu, Somalia. Front. Public Health. 2023;11:1203640. DOI: 10.3389/ fpubh.2023.1203640.
2. Rule AD, Krambeck AE, Lieske JC. Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol. 2011;6(8):2069-75. DOI: 10.2215/CJN.10651110.
3. Shastri S, Patel J, Sambandam KK, Lederer ED. Kidney Stone Pathophysiology, Evaluation and Management: Core Curriculum 2023. American Journal of Kidney Diseases. 2023;82(5):617-634. DOI: 10.1053/j.ajkd.2023.03.017.
4. Geraghty RM, Davis NF, Tzelves L, Lombardo R, Yuan C, Thomas K, et al. Best practice in interventional management of urolithiasis: an update from the European Association of Urology guidelines panel for urolithiasis 2022. Eur Urol Focus. 2023;9:199-208. DOI: 10.1016/j. euf.2022.06.014.
5. Wang X, Chen J, Xu J, Xie J, Harris DCH, Zheng G. The Role of Macrophages in Kidney Fibrosis. Front Physiol. 2021;12:705838. DOI: 10.3389/fphys.2021.705838.
6. Li G, Yang H, Zhang D, Zhang Y, Liu B, Wang Y, Zhou H, et al. The role of macrophages in fibrosis of chronic kidney disease, Biomedicine & Pharmacotherapy. 2024;177:117079. DOI: https://doi.org/10.1016/j.biopha. 2024.117079.
7. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: The master regulator of fibrosis. Nat. Rev. Nephrol. 2016;12:325-338. DOI: 10.1038/ nrneph.2016.48.
8. Reiss AB, Jacob B, Zubair A, Srivastava A, Johnson M, De Leon J. Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets. J Clin Med. 2024;13(7):1881. DOI: 10.3390/jcm13071881.
9. Matuszewska Ju, Krawiec A, Radziemski A, Uruski P, Tykarski A, Mikuła-Pietrasik Ju, et al. Alterations of receptors and insulin-like growth factor binding proteins in senescent cells. European Journal of Cell Biology. 2024;103(3):151438. DOI: https://doi.org/10.1016/j. ejcb.2024.151438.
10. Engvall E. The ELISA, Enzyme-Linked Immunosorbent Assay. Clinical Chemistry. 2010;56(2):319-320 DOI: https://doi.org/10.1373/ clinchem. 2009.127803.
11. Sureshbabu A, Muhsin SA, Choi ME. TGF-β signaling in the kidney: profibrotic and protective effects. Am J Physiol Renal Physiol. 2016;310(7):F596-F606. DOI: 10.1152/ajprenal.00365.2015.
12. Gu YY, Liu XS, Huang XR, Yu XQ, Lan HY. Diverse Role of TGF-β in Kidney Disease. Front. Cell Dev. Biol. 2020;8:123. DOI: 10.3389/ fcell. 2020.00123.
13. Higgins CE, Tang J, Higgins SP, Gifford CC, Mian BM, Jones DM, et al. The Genomic Response to TGF-β1 Dictates Failed Repair and Progression of Fibrotic Disease in the Obstructed Kidney. Front. Cell Dev. Biol. 2021;9:678524.
14. Campbell MG, Cormier A, Ito S, Seed RI, Bondesson AJ, Lou J, et al. Cryo-EM reveals integrin-mediated TFG-β activation without release from latent TGF-β. Cell. 2020;180:490-501. DOI: 10.1016/j.cell.2019.12.030.

Publication of the article:

«Bulletin of problems biology and medicine», 2025 Issue 1, 176, 194-200 pages, index UDC 616.613/.617-007.272-036.11-07:577.112

DOI:

10.29254/2077-4214-2025-1-176-194-200